

***ortho*-Naphthoquinone-Catalyzed Aerobic Oxidation of Amines to Fused Pyrimidin-4(3*H*)-  
ones: A Convergent Synthetic Route to Bouchardatine and Sildenafil**

Kyeongha Kim, Hun Young Kim and Kyungsoo Oh\*

Center for Metareceptome Research, Graduate School of Pharmaceutical Sciences, Chung-Ang  
University, 84 Heukseok-ro, Dongjak, Seoul 06974, Republic of Korea


**Table of Contents**

<b>General Methods</b>	<b>S2</b>
<b>2-Amino-aryl Benzamide Starting Materials</b>	<b>S2</b>
<b>Aryl Amine Starting Materials</b>	<b>S5</b>
<b>Preparation of <i>ortho</i>-Naphthoquinones Catalysts</b>	<b>S6</b>
<b>General Procedure A for the Synthesis of Fused Pyrimidin-4(3<i>H</i>)-ones:</b>	<b>S6</b>
<b>1.0 mmol Scale Reaction</b>	<b>S6</b>
<b>Characterization of the Products in Table 1, Scheme 2 and 3</b>	<b>S7</b>
<b>Synthesis of Bouchardatine in Scheme 5</b>	<b>S17</b>
<b>Synthesis of Sildenafil in Scheme 5</b>	<b>S18</b>
<b>References</b>	<b>S20</b>
<b><sup>1</sup>H &amp; <sup>13</sup>C NMR Spectra</b>	<b>S23</b>

## General Methods


All reactions were carried out with oven-dried glassware. The progress of all reactions was monitored by thin-layer chromatography on Dynamic Adsorbent, Inc. precoated silica gel plates (250  $\mu\text{m}$ ) and visualized by ultra-violet light or by staining with  $\text{KMnO}_4$  stain. HPLC grade solvents were used without further drying. Unless otherwise specified, all chemicals were purchased from Acros or Alfa Aesar or TCI and all solvents were purchased from Fischer Scientific. The microwave assisted reactions were carried out in Anton Paar microwave 400 synthesis reactor.  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were recorded in  $\text{CDCl}_3$  and  $\text{DMSO-d}_6$  on JEOL 600 MHz Fourier transform spectrometers at ambient temperature. The coupling constant  $J$  is given in Hz. The chemical shifts are reported in ppm on a scale downfield from TMS as an internal standard, and signal patterns are indicated as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet. For high resolution mass spectrometry (HRMS),  $m/z$  ratios are reported as values in atomic mass units. Silica gel (32-64u, Dynamic Adsorbent, Inc.) was used for column chromatography. The infrared spectra were obtained using a Agilent Cary 630 FRIR Spectrometer. Melting points were recorded on a Buchi-B-450 melting point apparatus and the values were uncorrected.

## 2-Amino-aryl Benzamide Starting Materials




2-Amino-aryl benzamide **1a-1c**, **1k**, **1n** and **1o** are commercially available. The compounds **1j**, **1l** are prepared according to literature procedure and the  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were compared with previously reported literature data.<sup>1-2</sup> **1d-1i** and **1m** were synthesized based on the literature procedure with slight modification.<sup>3-4</sup>

### 1) Synthesis of 2-Amino-aryl Benzamides (Method A for **1d**, **1e**, **1f** and **1m**)




Benzonitrile compounds (1.0 mmol) and  $\text{Cs}_2\text{CO}_3$  (1.0 equiv) were added into a 10 mL microwave reaction vial and 8.5 mL of deionized water was added. After irradiation under microwave at 150 °C for 25 min-2 h, the reaction mixture was cooled down and concentrated under reduced pressure. The residue was dissolved in acetone, dried over  $\text{Na}_2\text{SO}_4$ , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (eluent: 2-5% MeOH in DCM) to give **1d-1f**, **1m** in 70-90% yields.

### 2) Synthesis of 2-Amino-aryl Benzamides (Method B for **1g-1i**)




To a flask charged with anthranilic acid (1.0 mmol) and 1,1'-carbonyldiimidazole (1.0 equiv), was added 4 mL of anhydrous DMF under argon. The reaction was stirred at 40 °C for 12 h. After cooling down to ambient temperature, amine (1.0 equiv) was added and reaction was further stirred for 2 h. The reaction mixture was extracted with ethyl acetate (20 mL x 3) and washed with brine, dried over  $\text{Na}_2\text{SO}_4$ , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (eluent: 20% ethyl acetate in hexanes) to give **1g-1i** in 67-92% yields.

### 3) Characterization of Aryl Benzamide Starting Materials:




**2-Amino-5-methylbenzamide (**1d**):** The product **1d** was prepared by the Method A using 2-amino-5-methylbenzonitrile (132.1 mg, 1.0 mmol). The pure product was obtained by column chromatography on silica gel using 3% MeOH in  $\text{CH}_2\text{Cl}_2$  as eluent. 130.4 mg (80%); Pale yellow solid; The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra for this compound are consistent with the previously reported literature.<sup>5</sup>  $^1\text{H}$ -NMR (DMSO- $d_6$ , 600 MHz):  $\delta$  7.62 (s, 1H), 7.31 (d,  $J = 1.8$  Hz, 1H), 6.96 (s, 1H), 6.92 (dd,  $J = 8.4, 1.8$  Hz, 1H), 6.55 (d,  $J$


= 8.4 Hz, 1H), 6.28 (s, 2H), 2.11 (s, 3H);  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , 150 MHz):  $\delta$  171.3, 147.8, 132.7, 128.6, 122.7, 116.5, 113.7, 20.0.




**2-Amino-4-chlorobenzamide (1e):** The product **1e** was prepared by the Method A using 2-amino-4-chlorobenzonitrile (152.5 mg, 1.0 mmol). The pure product was obtained by column chromatography on silica gel using 2% MeOH in CH<sub>2</sub>Cl<sub>2</sub> as eluent. 153.5 mg (90%); Pale yellow solid; The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra for this compound are consistent with the previously reported literature.<sup>6</sup>  $^1\text{H}$ -NMR (DMSO- $d_6$ , 600 MHz):  $\delta$  7.77 (s, 1H), 7.53 (d,  $J$  = 8.4 Hz, 1H), 7.14 (s, 1H), 6.82 (s, 2H), 6.73 (d,  $J$  = 1.8 Hz, 1H), 6.47 (dd,  $J$  = 8.4, 1.8 Hz, 1H);  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , 150 MHz):  $\delta$  170.4, 151.5, 136.3, 130.6, 115.1, 114.0, 112.4.



**2-Amino-4-methylbenzamide (1f):** The product **1f** was prepared by the Method A using 2-amino-4-methylbenzonitrile (132.1 mg, 1.0 mmol). The pure product was obtained by column chromatography on silica gel using 3% MeOH in CH<sub>2</sub>Cl<sub>2</sub> as eluent. 112.5 mg (75%); White solid; The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra for this compound are consistent with the previously reported literature.<sup>7</sup>  $^1\text{H}$ -NMR (DMSO- $d_6$ , 600 MHz):  $\delta$  7.61 (s, 1H), 7.42 (d,  $J$  = 8.4 Hz, 1H), 6.92 (s, 1H), 6.52 (s, 2H), 6.46 (s, 1H), 6.28 (d,  $J$  = 8.4 Hz, 1H), 2.15 (s, 3H);  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , 150 MHz):  $\delta$  171.2, 150.3, 141.6, 128.8, 116.4, 115.6, 111.1, 21.0.




**2-Amino-N-methylbenzamide (1g):** The product **1g** was prepared by the Method B using anthranilic acid (137.1 mg, 1.0 mmol) and methyl amine (40 wt% solution in water, 83  $\mu\text{L}$ , 1.0 mmol). The pure product was obtained by column chromatography on silica gel using 20% ethyl acetate in hexanes as eluent. 100.6 mg (67%); White solid; The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra for this compound are consistent with the previously reported literature.<sup>8</sup>  $^1\text{H}$ -NMR (CDCl<sub>3</sub>, 600 MHz):  $\delta$  7.27-7.29 (m, 1H), 7.20-7.17 (m, 1H), 6.67-6.61 (m, 2H), 6.15 (s, 1H), 5.49 (s, 2H), 2.94 (d,  $J$  = 4.8 Hz, 3H);  $^{13}\text{C}$ -NMR (CDCl<sub>3</sub>, 150 MHz):  $\delta$  170.1, 148.7, 132.3, 127.2, 117.4, 116.7, 116.4, 26.6.




**2-Amino-N-benzylbenzamide (1h):** The product **1h** was prepared by the Method B using anthranilic acid (137.1 mg, 1.0 mmol) and benzylamine (109  $\mu\text{L}$ , 1.0 mmol). The pure product was obtained by column chromatography on silica gel using 20% ethyl acetate in hexanes as eluent. 203.6 mg (90%); White solid; The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra for this compound are consistent with the previously reported literature.<sup>8</sup>  $^1\text{H}$ -NMR (CDCl<sub>3</sub>, 600 MHz):  $\delta$  7.37-7.28 (m, 6H), 7.19-7.21 (m, 1H), 6.68 (d,  $J$  = 8.4 Hz, 1H), 6.61-6.63 (m, 1H), 6.40 (s, 1H), 5.55 (s, 2H), 4.59 (d,  $J$  = 5.4 Hz, 2H);  $^{13}\text{C}$ -NMR (CDCl<sub>3</sub>, 150 MHz):  $\delta$  169.3,

149.0, 138.4, 132.5, 128.9, 127.9, 127.6, 127.2, 117.5, 116.7, 115.9, 43.8.



**2-Amino-N-phenylbenzamide (1i):** The product **1i** was prepared by the Method B using anthranilic acid (137.1 mg, 1.0 mmol) and aniline (91  $\mu$ L, 1.0 mmol). The pure product was obtained by column chromatography on silica gel using 20% ethyl acetate in hexanes as eluent.


195.2 mg (92%); White solid; The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra for this compound are consistent with the previously reported literature.<sup>8</sup>  $^1\text{H}$ -NMR ( $\text{CDCl}_3$ , 600 MHz):  $\delta$  7.75 (s, 1H), 7.56 (d,  $J = 7.8$  Hz, 2H), 7.46 (d,  $J = 8.4$  Hz, 1H), 7.36 (t,  $J = 7.8$  Hz, 2H), 7.26-7.23 (m, 1H), 7.12-7.15 (m, 1H), 6.69-6.71 (m, 2H), 5.47 (s, 2H);  $^{13}\text{C}$ -NMR ( $\text{CDCl}_3$ , 150 MHz):  $\delta$  167.7, 149.1, 138.0, 132.9, 129.2, 127.3, 124.6, 120.7, 117.7, 117.0, 116.4.



**2-Aminobenzo[*b*]thiophene-3-carboxamide (1m):** The product **1m** was prepared by the Method A using 2-aminobenzo[*b*]thiophene-3-carbonitrile (174.22 mg, 1.0 mmol). The pure product was obtained by column chromatography on silica gel using 5% MeOH in  $\text{CH}_2\text{Cl}_2$  as eluent. 134.5 mg

(70%); White solid, m.p. 188-191  $^\circ\text{C}$ ;  $^1\text{H}$ -NMR ( $\text{DMSO-}d_6$ , 600 MHz):  $\delta$  7.67 (s, 2H), 7.66 (d,  $J = 10.2$  Hz, 1H), 7.60 (d,  $J = 7.2$  Hz, 1H), 7.20-7.22 (m, 1H), 7.01 (t,  $J = 7.2$  Hz, 1H), 6.98 (s, 2H);  $^{13}\text{C}$ -NMR ( $\text{DMSO-}d_6$ , 150 MHz):  $\delta$  167.8, 161.6, 137.1, 128.7, 124.8, 121.7, 120.8, 119.9, 100.8. IR (neat): 3470, 3391, 3265, 3162, 2937, 2855, 1638, 1576, 1466  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$  calcd for  $\text{C}_9\text{H}_5\text{NOS}$  [ $\text{M-NH}_3$ ] $^+$  176.0164 Found 176.0169.

### Aryl Amine Starting Materials:




All of aryl amine substrates are commercially available except **2r**. For the synthesis of **2r**, please refer to the following

sildenafil synthesis section.

### Preparation of *ortho*-Naphthoquinones Catalysts:

*ortho*-Naphthoquinone catalysts were prepared by the previously reported method.<sup>9</sup>




### General Procedure A for the Synthesis of Fused Pyrimidin-4(3*H*)-ones:

To a dried flask charged with catalyst **o-NQ1** (0.01 mmol, 5 mol%), aryl benzamide (0.2 mmol), aryl benzylamine (0.24 mmol) were added 1.0 mL of DMSO followed by TFA (0.04 mmol, 20 mol%). The reaction was stirred under O<sub>2</sub> balloon at 100-120 °C for 12-36 h. The reaction mixture was cooled down to ambient temperature, diluted with 10 mL of water, and extracted with ethyl acetate (10 mL x 3). The combined organic phase was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: 30-40% acetone in hexanes or 20-40% ethyl acetate in hexanes) to give the desired products **4a-4zh** in 23-97% yields.


#### 1.0 mmol Scale Reaction

To a dried flask charged with catalyst **o-NQ1** (11.7 mg, 0.05 mmol, 5 mol%), benzamide (136.2 mg, 1.0 mmol), benzylamine (131 μL, 1.2 mmol) were added 5.0 mL of DMSO followed by TFA (15 μL, 0.2 mmol, 20 mol %). The reaction was stirred under O<sub>2</sub> balloon at 100 °C for 36 h. The reaction mixture was cooled down to ambient temperature, diluted with 20 mL of water, and extracted with ethyl acetate (20 mL x 3). The combined organic phase was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: 30% Acetone in hexanes) to give the desired product **6a** in 85% yield (186 mg).


### Characterization of the Products in Table 1, Scheme 2 and 3




**2-Phenyl-2,3-dihydroquinazolin-4(1H)-one (3a):** The product **3a** was prepared by the General Procedure A (CH<sub>3</sub>CN was used as solvent instead of DMSO) using **1a** (27.2 mg, 0.2 mmol) and **2a** (26  $\mu$ L, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 30% acetone in hexanes as eluent. 35.8 mg (80%); white solid; The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for this compound are consistent with previously reported literature data.<sup>10</sup> <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 600 MHz):  $\delta$  8.27 (s, 1H), 7.60-7.59 (m, 1H), 7.47-7.48 (m, 2H), 7.39-7.32 (m, 3H), 7.21-7.24 (m, 1H), 7.10 (s, 1H), 6.73 (d,  $J$  = 8.4 Hz, 1H), 6.64-6.67 (m, 1H), 5.74 (s, 1H); <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>, 150 MHz):  $\delta$  163.5, 147.8, 141.6, 133.3, 128.4, 128.3, 127.3, 126.8, 117.1, 114.9, 114.4, 66.5.



**2-Phenylquinazolin 4(3H)-one (4a):** The product **4a** was prepared by the General Procedure A using **1a** (27.2 mg, 0.2 mmol) and **2a** (26  $\mu$ L, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 30% acetone in hexanes as eluent. 41 mg (93%); white solid; The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for this compound are consistent with previously reported literature data.<sup>11</sup> <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 600 MHz):  $\delta$  11.73 (s, 1H), 8.34 (d,  $J$  = 7.8 Hz, 1H), 8.25-8.27 (m, 2H), 7.85-7.80 (m, 2H), 7.58-7.59 (m, 3H), 7.50-7.52 (m, 1H); <sup>13</sup>C-NMR (CDCl<sub>3</sub>, 150 MHz):  $\delta$  164.1, 151.9, 149.7, 135.0, 133.0, 131.8, 129.2, 128.2, 127.6, 126.9, 126.5, 121.0.




**2-(p-Tolyl)quinazolin-4(3H)-one (4b):** The product **4b** was prepared by the General Procedure A using **1a** (27.2 mg, 0.2 mmol) and **2b** (30  $\mu$ L, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 30% ethyl acetate in hexanes as eluent. 46 mg (97%); white solid; The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for this compound are consistent with previously reported literature data.<sup>12</sup> <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 600 MHz):  $\delta$  12.45 (s, 1H), 8.13 (d,  $J$  = 8.4 Hz, 1H), 8.07-8.09 (m, 2H), 7.82-7.79 (m, 1H), 7.70-7.71 (m, 1H), 7.47-7.50 (m, 1H), 7.32-7.33 (m, 2H), 2.36 (s, 3H); <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>, 150 MHz):  $\delta$  162.3, 152.2, 148.8, 141.4, 134.5, 129.9, 129.1, 127.7, 127.3, 126.3, 125.8, 120.9, 21.0.




**2-(4-(tert-Butyl)phenyl)quinazolin-4(3H)-one (4c):** The product **4c** was prepared by the General Procedure A using **1a** (27.2 mg, 0.2 mmol) and **2c** (42  $\mu$ L, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 20% acetone in hexanes as eluent. 47 mg (84%); white solid; The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for this


compound are consistent with previously reported literature data.<sup>14</sup> <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 600 MHz): δ 11.43 (s, 1H), 8.35 (d, *J* = 7.2 Hz, 1H), 8.18-8.20 (m, 2H), 7.83 (d, *J* = 7.2 Hz, 1H), 7.79 (t, *J* = 7.2 Hz, 1H), 7.59-7.60 (m, 2H), 7.50 (t, *J* = 7.2 Hz, 1H), 1.40 (s, 9H); <sup>13</sup>C-NMR (CDCl<sub>3</sub>, 150 MHz): δ 163.9, 155.4, 151.9, 149.9, 134.9, 130.2, 128.2, 127.3, 126.7, 126.5, 126.2, 121.1, 35.2, 31.3.



**2-(4-Methoxyphenyl)quinazolin-4(3H)-one (4d):** The product **4d** was prepared by the General Procedure A using **1a** (27.2 mg, 0.2 mmol) and **2d** (31 μL, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 30% ethyl acetate in hexanes as eluent. 46 mg (92%); white solid; The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for this compound are consistent with previously reported literature data.<sup>12</sup> <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>, 600 MHz): δ 12.40 (s, 1H), 8.17-8.18 (m, 2H), 8.12 (d, *J* = 6.6 Hz, 1H), 7.78-7.80 (m, 1H), 7.68-7.69 (m, 1H), 7.45-7.47 (m, 1H), 7.06-7.08 (m, 2H), 3.83 (s, 3H); <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>, 150 MHz): δ 162.4, 161.8, 151.9, 148.9, 134.5, 129.4, 127.2, 126.1, 125.8, 124.8, 120.7, 114.0, 55.4.




**2-(4-Chlorophenyl)quinazolin-4(3H)-one (4e):** The product **4e** was prepared by the General Procedure A using **1a** (27.2 mg, 0.2 mmol) and **2e** (30 μL, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 30% acetone in hexanes as eluent. 38 mg (75%); white solid; The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for this compound are consistent with previously reported literature data.<sup>12</sup> <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>, 600 MHz): δ 12.60 (s, 1H), 8.18-8.20 (m, 2H), 8.15 (d, *J* = 7.2 Hz, 1H), 7.84 (t, *J* = 7.2 Hz, 1H), 7.73 (d, *J* = 7.2 Hz, 1H), 7.61-7.62 (m, 2H), 7.53 (t, *J* = 7.2 Hz, 1H); <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>, 150 MHz): δ 162.2, 151.4, 148.5, 136.3, 134.7, 131.5, 129.6, 128.7, 127.5, 126.8, 125.9, 121.0.




**2-(4-Bromophenyl)quinazolin-4(3H)-one (4f):** The product **4f** was prepared by the General Procedure A using **1a** (27.2 mg, 0.2 mmol) and **2f** (30 μL, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 30% acetone in hexanes as eluent. 35 mg (58%); white solid; The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for this compound are consistent with previously reported literature data.<sup>13</sup> <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>, 600 MHz): δ 12.34 (s, 1H), 8.12-8.16 (m, 3H), 7.82 (t, *J* = 7.2 Hz, 1H), 7.72-7.74 (m, 3H), 7.52 (t, *J* = 7.2 Hz, 1H); <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>, 150 MHz): δ 161.7, 151.2, 148.2, 134.1, 131.7, 131.1, 129.4, 127.0, 126.2, 125.4, 124.7, 120.7.







**2-(*m*-Tolyl)quinazolin-4(3*H*)-one (4g):** The product **4g** was prepared by the General Procedure A using **1a** (27.2 mg, 0.2 mmol) and **2g** (30  $\mu$ L, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 20% acetone in hexanes as eluent. 42 mg (90%) white solid; The  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra for this compound are consistent with previously reported literature data.<sup>13</sup>  $^1\text{H}$ -NMR (DMSO- $d_6$ , 600 MHz):  $\delta$  12.46 (s, 1H), 8.13-8.14 (m, 1H), 8.01 (s, 1H), 7.96 (d,  $J$  = 7.2 Hz, 1H), 7.80-7.82 (m, 1H), 7.72-7.73 (m, 1H), 7.48-7.51 (m, 1H), 7.43-7.37 (m, 2H), 2.39 (s, 3H);  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , 150 MHz):  $\delta$  162.2, 152.3, 148.8, 137.9, 134.5, 132.6, 132.0, 128.5, 128.3, 127.5, 126.5, 125.8, 124.9, 121.0, 20.9.



**2-(3-Methoxyphenyl)quinazolin-4(3*H*)-one (4h):** The product **4h** was prepared by the General Procedure A using **1a** (27.2 mg, 0.2 mmol) and **2h** (31  $\mu$ L, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 30% acetone in hexanes as eluent. 43 mg (83%); white solid; The  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra for this compound are consistent with previously reported literature data.<sup>10</sup>  $^1\text{H}$ -NMR (DMSO- $d_6$ , 600 MHz):  $\delta$  12.52 (s, 1H), 8.14 (d,  $J$  = 7.2 Hz, 1H), 7.78-7.82 (m, 2H), 7.72-7.74 (m, 2H), 7.48-7.51 (m, 1H), 7.42-7.44 (m, 1H), 7.18-7.13 (m, 1H), 3.85 (s, 3H);  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , 150 MHz):  $\delta$  162.5, 159.3, 152.2, 148.7, 134.5, 134.2, 129.7, 127.4, 126.5, 125.8, 121.0, 120.1, 117.5, 112.5, 55.4.




**2-(3-Chlorophenyl)quinazolin-4(3*H*)-one (4i):** The product **4i** was prepared by the General Procedure A using **1a** (27.2 mg, 0.2 mmol) and **2i** (29  $\mu$ L, 0.3 mmol). The pure product was obtained by column chromatography on silica gel using 30% acetone in hexanes as eluent. 49 mg (91%); white solid; The  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra for this compound are consistent with previously reported literature data.<sup>13</sup>  $^1\text{H}$ -NMR (DMSO- $d_6$ , 600 MHz):  $\delta$  12.36 (s, 1H), 8.24 (s, 1H), 8.14-8.16 (m, 2H), 7.81-7.84 (m, 1H), 7.75 (d,  $J$  = 8.4 Hz, 1H), 7.62 (d,  $J$  = 8.4 Hz, 1H), 7.51-7.57 (m, 2H);  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , 150 MHz):  $\delta$  161.7, 150.8, 148.1, 134.6, 134.0, 133.1, 130.6, 129.9, 127.1, 127.0, 126.3, 126.0, 125.4, 120.8.




**2-(*o*-Tolyl)quinazolin-4(3*H*)-one (4j):** The product **4j** was prepared by the General Procedure A using **1a** (27.2 mg, 0.2 mmol) and **2j** (30  $\mu$ L, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 20% acetone in hexanes as eluent. 38 mg (81%); white solid; The  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra for this compound are consistent with previously reported literature


data.<sup>13</sup> <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 600 MHz): δ 12.44 (s, 1H), 8.16 (d, *J* = 8.4 Hz, 1H), 7.83-7.81 (m, 1H), 7.67-7.68 (m, 1H), 7.54-7.49 (m, 2H), 7.40-7.43 (m, 1H), 7.30-7.34 (m, 2H), 2.38 (s, 3H); <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>, 150 MHz): δ 161.8, 154.3, 148.7, 136.1, 134.4, 134.2, 130.5, 129.9, 129.1, 127.3, 126.6, 125.8, 125.7, 121.0, 19.5.




**2-(2-Chlorophenyl)quinazolin-4(3H)-one (4k):** The product **4k** was prepared by the General Procedure A using **1a** (27.2 mg, 0.2 mmol) and **2k** (29 μL, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 20% acetone in hexanes as eluent. 40 mg (79%); white solid; The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for this compound are consistent with previously reported literature data.<sup>12</sup> <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 600 MHz): δ 10.24 (s, 1H), 8.29 (d, *J* = 8.4 Hz, 1H), 7.84-7.79 (m, 3H), 7.51-7.54 (m, 2H), 7.47-7.49 (m, 1H), 7.43-7.46 (m, 1H); <sup>13</sup>C-NMR (CDCl<sub>3</sub>, 150 MHz): δ 162.1, 151.1, 149.1, 135.0, 132.8, 132.2, 132.0, 131.6, 130.8, 128.2, 127.7, 127.6, 126.7, 121.3.



**2-(2-Fluorophenyl)quinazolin-4(3H)-one (4l):** The product **4l** was prepared by the General Procedure A using **1a** (27.2 mg, 0.2 mmol) and **2l** (27 μL, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 20% acetone in hexanes as eluent. 35 mg (83%); white solid; The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for this compound are consistent with previously reported literature data.<sup>15</sup> <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 600 MHz): δ 10.07 (s, 1H), 8.36-8.33 (m, 1H), 8.30 (d, *J* = 7.2 Hz, 1H), 7.80-7.81 (m, 2H), 7.56-7.50 (m, 2H), 7.34-7.36 (m, 1H), 7.23 (dd, *J* = 12.4, 8.3 Hz, 1H); <sup>13</sup>C-NMR (CDCl<sub>3</sub>, 150 MHz): δ 162.0, 160.9 (d, *J* = 248.6 Hz), 149.1, 148.4, 134.9, 133.7 (d, *J* = 8.7 Hz), 131.5, 128.2, 127.4, 126.7, 125.4, 121.4, 120.2 (d, *J* = 8.6 Hz), 116.8 (d, *J* = 23.1 Hz).




**2-(3,5-Dimethoxyphenyl)quinazolin-4(3H)-one (4m):** The product **4m** was prepared by the General Procedure A using **1a** (27.2 mg, 0.2 mmol) and **2m** (40 mg, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 30% acetone in hexanes as eluent. 34 mg (60%); white solid; The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for this compound are consistent with previously reported literature data.<sup>13</sup> <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 600 MHz): δ 12.49 (s, 1H), 8.13-8.14 (m, 1H), 7.83-7.80 (m, 1H), 7.72-7.74 (m, 1H), 7.49-7.52 (m, 1H), 7.37-7.38 (m, 2H), 6.67-6.68 (m, 1H), 3.83 (s, 6H); <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>, 150 MHz): δ 162.2, 160.5, 151.9, 148.5, 134.5, 127.5, 126.6, 125.8, 121.0, 105.5 (2C), 103.8, 55.5.




**2-(Naphthalen-1-yl)quinazolin-4(3H)-one (4n):** The product **4n** was prepared by the General Procedure A using **1a** (27.2 mg, 0.2 mmol) and **2n** (36  $\mu$ L, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 20% acetone in hexanes as eluent. 37 mg (66%); white solid; The  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra for this compound are consistent

with previously reported literature data.<sup>12</sup>  $^1\text{H}$ -NMR (DMSO- $d_6$ , 600 MHz):  $\delta$  12.67 (s, 1H), 8.21 (d,  $J = 7.2$  Hz, 1H), 8.16 (d,  $J = 7.2$  Hz, 1H), 8.10-8.12 (m, 1H), 8.03-8.04 (m, 1H), 7.84-7.87 (m, 1H), 7.78-7.79 (m, 1H), 7.72-7.73 (m, 1H), 7.62-7.65 (m, 1H), 7.61-7.56 (m, 3H);  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , 150 MHz):  $\delta$  161.9, 153.7, 148.7, 134.5, 133.1, 131.7, 130.4, 130.2, 128.3, 127.7, 127.5, 127.1, 126.8, 126.4, 125.8, 125.2, 125.1, 121.2.




**2-(Furan-2-yl)quinazolin-4(3H)-one (4o):** The product **4o** was prepared by the General Procedure A using **1a** (27.2 mg, 0.2 mmol) and **2o** (23  $\mu$ L, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 30% acetone in hexanes as eluent. 23 mg (54%); white solid; The  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra for this compound are consistent with previously reported

literature data.<sup>13</sup>  $^1\text{H}$ -NMR (DMSO- $d_6$ , 600 MHz):  $\delta$  12.50 (s, 1H), 8.10-8.11 (m, 1H), 7.99 (s, 1H), 7.81-7.78 (m, 1H), 7.67-7.68 (m, 1H), 7.61-7.62 (m, 1H), 7.48 (t,  $J = 7.2$  Hz, 1H), 6.73-6.74 (m, 1H);  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , 150 MHz):  $\delta$  161.2, 148.5, 146.1, 146.0, 143.8, 134.2, 127.0, 126.1, 125.6, 121.0, 114.1, 112.2.



**2-(Thiophen-2-yl)quinazolin-4(3H)-one (4p):** The product **4p** was prepared by the General Procedure A using **1a** (27.2 mg, 0.2 mmol) and **2p** (25  $\mu$ L, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 20% acetone in hexanes as eluent. 35 mg (75%); white solid; The  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra for this compound are consistent with previously reported


literature data.<sup>13</sup>  $^1\text{H}$ -NMR (DMSO- $d_6$ , 600 MHz):  $\delta$  12.65 (s, 1H), 8.22 (m, 1H), 8.12-8.11 (m, 1H), 7.85-7.86 (m, 1H), 7.81-7.78 (m, 1H), 7.63-7.64 (m, 1H), 7.46-7.48 (m, 1H), 7.21-7.23 (m, 1H);  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , 150 MHz):  $\delta$  161.8, 148.6, 147.8, 137.3, 134.7, 132.1, 129.4, 128.5, 126.9, 126.3, 126.0, 120.8.




**6-Chloro-2-phenylquinazolin-4(3H)-one (4q):** The product **4q** was prepared by the General Procedure A using **1b** (34.1 mg, 0.2 mmol) and **2a** (26  $\mu$ L, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 30% acetone in hexanes

as eluent. 43 mg (84%); white solid; The  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra for this compound are consistent with previously reported literature data.<sup>14</sup>  $^1\text{H}$ -NMR (DMSO- $d_6$ , 600 MHz):  $\delta$  12.70 (s, 1H), 8.15-8.16 (m, 2H), 8.06-8.07


(m, 1H), 7.83-7.85 (m, 1H), 7.74-7.75 (m, 1H), 7.57-7.60 (m, 1H), 7.52-7.55 (m, 2H); <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>, 150 MHz): δ 161.3, 152.9, 147.4, 134.7, 132.5, 131.6, 130.7, 129.7, 128.6, 127.8, 124.9, 122.2.




**6-Chloro-2-(p-tolyl)quinazolin-4(3H)-one (4r):** The product **4r** was prepared by the General Procedure A using **1b** (34.1 mg, 0.2 mmol) and **2b** (30 μL, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 30% acetone in hexanes as eluent. 45 mg (83%); white solid; The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for this compound are consistent with previously reported literature data.<sup>12</sup> <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 600 MHz): δ 12.25 (s, 1H), 8.06-8.09 (m, 3H), 7.79-7.81 (m, 1H), 7.71-7.73 (m, 1H), 7.34-7.35 (m, 2H), 2.40 (s, 3H); <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>, 150 MHz): δ 160.9, 152.5, 147.2, 141.2, 134.1, 130.2, 129.4, 129.1, 128.7, 127.4, 124.5, 121.8, 20.5.



**6-Chloro-2-(3-methoxyphenyl)quinazolin-4(3H)-one (4s):** The product **4s** was prepared by the General Procedure A using **1b** (34.1 mg, 0.2 mmol) and **2h** (30 μL, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 20% acetone in hexanes as eluent. 43 mg (74%); white solid, m.p. 278-279 °C; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 600 MHz): δ 12.38 (s, 1H), 8.08 (s, 1H), 7.82-7.75 (m, 4H), 7.43-7.45 (m, 1H), 7.14-7.15 (m, 1H), 3.87 (s, 3H); <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>, 150 MHz): δ 160.7, 159.1, 152.3, 146.9, 134.0, 133.5, 130.3, 129.1(2), 129.0(5), 124.4, 121.9, 119.8, 117.3, 112.6, 55.1; IR(neat): 3175, 3034, 2922, 2844, 1677, 1580, 1463, 1287, 1237 cm<sup>-1</sup>; HRMS (ESI): m/z calcd for C<sub>15</sub>H<sub>12</sub>ClN<sub>2</sub>O<sub>2</sub> [M+H]<sup>+</sup> 287.0581 Found 287.0591.




**6-Fluoro-2-phenylquinazolin-4(3H)-one (4t):** The product **4t** was prepared by the General Procedure A using **1c** (30.8 mg, 0.2 mmol) and **2a** (26 μL, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 30% acetone in hexanes as eluent. 32 mg (67%); white solid; The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for this compound are consistent with previously reported literature data.<sup>10</sup> <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 600 MHz): δ 12.60 (s, 1H), 8.15-8.16 (m, 2H), 7.82-7.79 (m, 2H), 7.68-7.72 (m, 1H), 7.52-7.59 (m, 3H); <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>, 151 MHz): δ 161.7, 159.9 (d, J = 243.0 Hz), 151.9, 145.6, 132.6, 131.4, 130.2 (d, J = 4.4 Hz), 128.6, 127.7, 123.0 (d, J = 23.1 Hz), 122.1 (d, J = 8.7 Hz), 110.5 (d, J = 23.0 Hz).




**6-Fluoro-2-(p-tolyl)quinazolin-4(3H)-one (4u):** The product **4u** was prepared by the General Procedure A using **1c** (30.8 mg, 0.2 mmol) and **2b** (30 μL, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 30% acetone in


hexanes as eluent. 32 mg (63%); white solid, m.p. 275-277 °C; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 600 MHz): δ 12.58 (s, 1H), 8.05-8.07 (m, 2H), 7.81-7.77 (m, 2H), 7.71-7.68 (m, 1H), 7.32-7.34 (m, 2H), 2.37 (s, 3H); <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>, 150 MHz): δ 162.3, 160.4 (d, *J* = 244.1), 152.3, 146.2, 142.0, 130.7 (d, *J* = 5.7 Hz), 130.3, 129.7, 128.2, 123.5 (d, *J* = 24.5 Hz), 122.6 (d, *J* = 7.2 Hz), 111.0 (d, *J* = 23.1 Hz), 21.5; IR(neat): 3186, 3030, 2937, 1653, 1343, 1280 cm<sup>-1</sup>; HRMS (ESI): *m/z* calcd for C<sub>15</sub>H<sub>12</sub>FN<sub>2</sub>O [M+H]<sup>+</sup> 255.0928 Found 255.0930.




**6-Methyl-2-(*p*-tolyl)quinazolin-4(3*H*)-one (4v):** The product **4v** was prepared by the General Procedure A using **1d** (30.0 mg, 0.2 mmol) and **2b** (30 μL, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 20% acetone in hexanes as eluent. 40 mg (80%); white solid; The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for this compound are consistent with previously reported literature data.<sup>16</sup> <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 600 MHz): δ 12.15 (s, 1H), 8.08 (d, *J* = 8.4 Hz, 2H), 7.94 (s, 1H), 7.60-7.63 (m, 2H), 7.33 (d, *J* = 8.4 Hz, 2H), 2.45 (s, 3H), 2.39 (s, 3H); <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>, 150 MHz): δ 161.8, 151.2, 146.5, 140.8, 135.6, 135.3, 129.8, 128.7, 127.2, 126.8, 124.9, 120.4, 20.5, 20.4.



**7-Chloro-2-(*p*-tolyl)quinazolin-4(3*H*)-one (4w):** The product **4w** was prepared by the General Procedure A using **1e** (30.8 mg, 0.2 mmol) and **2b** (30 μL, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 30% acetone in hexanes as eluent. 33 mg (61%); white solid, m.p. 313-314 °C; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 600 MHz): δ 12.23 (s, 1H), 8.08-8.13 (m, 3H), 7.72 (s, 1H), 7.47-7.48 (m, 1H), 7.34-7.35 (m, 2H), 2.40 (s, 3H); <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>, 150 MHz): δ 161.1, 153.4, 149.5, 141.3, 138.6, 129.3, 128.6, 127.4, 127.3, 125.9, 125.8, 119.3, 20.4; IR(neat): 3190, 2918, 2864, 1673, 1556, 1479 cm<sup>-1</sup>; HRMS (ESI): *m/z* calcd for C<sub>15</sub>H<sub>12</sub>ClN<sub>2</sub>O [M+H]<sup>+</sup> 271.0632 Found 271.0639.




**7-Methyl-2-(*p*-tolyl)quinazolin-4(3*H*)-one (4x):** The product **4x** was prepared by the General Procedure A using **1f** (30.0 mg, 0.2 mmol) and **2b** (30 μL, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 30% acetone in hexanes as eluent. 38 mg (76%); white solid; The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for this compound are consistent with previously reported literature data.<sup>17</sup> <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 600 MHz): δ 12.18 (s, 1H), 8.07-8.08 (m, 2H), 8.02 (d, *J* = 7.8 Hz, 1H), 7.51 (s, 1H), 7.29-7.33 (m, 3H), 2.46 (s, 3H), 2.38 (s, 3H); <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>, 150 MHz): δ 161.8, 152.0, 148.7, 144.6, 141.0, 129.8, 128.8, 127.4, 127.3, 126.8, 125.4, 118.3, 21.0, 20.6.




**3-Methyl-2-phenylquinazolin-4(3H)-one (4y):** The product **4y** was prepared by the General Procedure A using **1g** (30.0 mg, 0.2 mmol) and **2a** (26  $\mu$ L, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 30% ethyl acetate in hexanes as eluent.

41 mg (88%); white solid; The  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra for this compound are consistent with previously reported literature data.<sup>18</sup>  $^1\text{H}$ -NMR ( $\text{CDCl}_3$ , 600 MHz):  $\delta$  8.33 (d,  $J = 8.4$  Hz, 1H), 7.73-7.75 (m, 2H), 7.57-7.49 (m, 6H), 3.50 (s, 3H);  $^{13}\text{C}$ -NMR ( $\text{CDCl}_3$ , 150 MHz):  $\delta$  162.9, 156.3, 147.5, 135.5, 134.4, 130.2, 129.0, 128.1, 127.6, 127.1, 126.8, 120.7, 34.4.




**3-Benzyl-2-phenylquinazolin-4(3H)-one (4z):** The product **4z** was prepared by the General Procedure A using **1h** (45.2 mg, 0.2 mmol) and **2a** (26  $\mu$ L, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 20% ethyl acetate in hexanes as eluent.

58 mg (93%); white solid; The  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra for this compound are consistent with previously reported literature data.<sup>19</sup>  $^1\text{H}$ -NMR ( $\text{CDCl}_3$ , 600 MHz):  $\delta$  8.38 (d,  $J = 8.4$  Hz, 1H), 7.80-7.76 (m, 2H), 7.54-7.52 (m, 1H), 7.45-7.47 (m, 1H), 7.38-7.41 (m, 2H), 7.32-7.35 (m, 2H), 7.19-7.20 (m, 3H), 6.92-6.93 (m, 2H), 5.28 (s, 2H);  $^{13}\text{C}$ -NMR ( $\text{CDCl}_3$ , 150 MHz):  $\delta$  162.6, 156.5, 147.4, 136.7, 135.4, 134.7, 130.0, 128.7, 128.6, 128.1, 127.7, 127.5, 127.3, 127.2, 127.1, 121.0, 48.9.



**2,3-Diphenylquinazolin-4(3H)-one (4za):** The product **4za** was prepared by the General Procedure A using **1i** (42.4 mg, 0.2 mmol) and **2a** (26  $\mu$ L, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 20% ethyl acetate in hexanes as eluent.


57 mg (95%); white solid; The  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra for this compound are consistent with previously reported literature data.<sup>18</sup>  $^1\text{H}$ -NMR ( $\text{CDCl}_3$ , 600 MHz):  $\delta$  8.36 (d,  $J = 7.6$  Hz, 1H), 7.84-7.80 (m, 2H), 7.55-7.53 (m, 1H), 7.14-7.34 (m, 10H);  $^{13}\text{C}$ -NMR ( $\text{CDCl}_3$ , 150 MHz):  $\delta$  162.4, 155.3, 147.6, 137.8, 135.6, 134.9, 129.4, 129.2, 129.1(2C), 128.5, 128.1, 127.9, 127.4, 127.3, 121.1.



**2-Phenylbenzo[g]quinazolin-4(3H)-one (4zb):** The product **4zb** was prepared by the General Procedure A using **1j** (37 mg, 0.2 mmol) and **2a** (26  $\mu$ L, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 20% acetone in


hexanes as eluent. 25 mg (46%); white solid; The  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra for this compound are consistent with previously reported literature data.<sup>1</sup>  $^1\text{H}$ -NMR ( $\text{DMSO}-d_6$ , 600 MHz):  $\delta$  12.20 (s, 1H), 8.85 (s, 1H), 8.30 (s, 1H),

8.22-8.24 (m, 2H), 8.19 (d,  $J = 8.4$  Hz, 1H), 8.10 (d,  $J = 8.4$  Hz, 1H), 7.66 (t,  $J = 7.2$  Hz, 1H), 7.60-7.55 (m, 4H);  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , 150 MHz):  $\delta$  162.4, 151.1, 143.9, 136.2, 132.8, 131.0, 130.7, 129.0, 128.3, 128.2, 127.5, 127.4, 127.0, 125.9, 124.6, 119.9.




**2-Phenylpyrido[2,3-d]pyrimidin-4(3H)-one (4zc):** The product **4zc** was prepared by the General Procedure A using **1k** (27.4 mg, 0.2 mmol) and **2a** (26  $\mu\text{L}$ , 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 30% acetone in hexanes as eluent.

41 mg (92%); white solid; The  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra for this compound are consistent with previously reported literature data.<sup>20</sup>  $^1\text{H}$ -NMR (DMSO- $d_6$ , 600 MHz):  $\delta$  12.82 (s, 1H), 8.95-8.96 (m, 1H), 8.52-8.51 (m, 1H), 8.20-8.21 (m, 2H), 7.60-7.63 (m, 1H), 7.55-7.57 (m, 2H), 7.51-7.53 (m, 1H),  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , 150 MHz):  $\delta$  163.0, 158.7, 156.1, 155.4, 135.5, 132.4, 131.9, 128.7, 128.1, 122.2, 116.2.




**2-Phenylpyrimido[4,5-b]quinolin-4(3H)-one (4zd):** The product **4zd** was prepared by the General Procedure A using **1l** (37.4 mg, 0.2 mmol) and **2a** (26  $\mu\text{L}$ , 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 3% MeOH in DCM

as eluent. 13 mg (23%); Yellow solid; The  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra for this compound are consistent with previously reported literature data.<sup>2</sup>  $^1\text{H}$ -NMR (DMSO- $d_6$ , 600 MHz):  $\delta$  12.40 (s, 1H), 9.25 (s, 1H), 8.29-8.30 (m, 2H), 8.22-8.24 (m, 1H), 8.07-8.09 (m, 1H), 7.91-7.93 (m, 1H), 7.58-7.65 (m, 4H);  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , 150 MHz):  $\delta$  163.2, 155.9, 155.8, 150.8, 137.6, 132.6, 132.2, 131.5, 129.0, 128.2, 128.0, 127.8, 125.9(2C), 115.2.




**2-Phenylbenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (4ze) :** The product **4zf** was prepared by the General Procedure A using **1m** (38.4 mg, 0.2 mmol) and **2a** (26  $\mu\text{L}$ , 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 20 %

acetone in hexanes as eluent. 37.8 mg (68%); white solid, m.p. 322-323  $^\circ\text{C}$ ;  $^1\text{H}$ -NMR (DMSO- $d_6$ , 600 MHz):  $\delta$  12.62 (s, 1H), 8.53 (d,  $J = 7.8$  Hz, 1H), 8.22 (d,  $J = 8.4$  Hz, 2H), 8.02 (d,  $J = 7.8$  Hz, 1H), 7.63-7.48 (m, 5H);  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , 150 MHz):  $\delta$  166.0, 157.9, 154.7, 134.6, 133.2, 131.5, 131.2, 128.1, 127.5, 125.5, 125.1, 123.4, 122.1, 115.4; IR(neat): 3086, 2972, 2933, 2864, 1662, 1533, 1448  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$  calcd for  $\text{C}_{16}\text{H}_{11}\text{N}_2\text{OS}$   $[\text{M}]^+$  279.0586 Found 279.0594.




**2-Phenyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (4zf):** The product **4zf** was prepared by the General Procedure A using **1n** (39.2 mg, 0.2 mmol) and **2a** (26  $\mu$ L, 0.24 mmol). The pure product was obtained by column chromatography on silica gel

using 20% acetone in hexanes as eluent. 24.2 mg (43%); white solid, m.p. 294-295  $^{\circ}$ C;  $^1$ H-NMR (DMSO- $d_6$ , 600 MHz):  $\delta$  12.22 (s, 1H), 8.10-8.12 (m, 2H), 7.57-7.49 (m, 3H), 2.92-2.93 (m, 2H), 2.75-2.77 (m, 2H), 1.86-1.77 (m, 4H);  $^{13}$ C-NMR (DMSO- $d_6$ , 150 MHz):  $\delta$  162.7, 158.3, 151.8, 132.1, 131.8, 130.7, 130.5, 128.1, 127.2, 120.6, 24.9, 24.2, 22.2, 21.4; IR(neat): 3076, 2933, 2858, 1653, 1533, 1483, 1284  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$  calcd for  $\text{C}_{16}\text{H}_{15}\text{N}_2\text{OS}$   $[\text{M}+\text{H}]^+$  283.0899 Found 283.0906.




**1-Methyl-5-phenyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one (4zg):** The product **4zg** was prepared by the General Procedure A using **1o** (36.8 mg, 0.2 mmol) and **2a** (26  $\mu$ L, 0.24 mmol). The pure product was obtained by column chromatography on silica gel using 30%

acetone in hexanes as eluent. 37 mg (70%); white solid; The  $^1$ H NMR and  $^{13}$ C NMR spectra for this compound are consistent with previously reported literature data.<sup>14</sup>  $^1$ H-NMR (DMSO- $d_6$ , 600 MHz):  $\delta$  12.13 (s, 1H), 8.06-8.07 (m, 2H), 7.53-7.49 (m, 3H), 4.15 (s, 3H), 2.82 (t,  $J = 7.2$  Hz, 2H), 1.76-1.82 (m, 2H), 0.97 (t,  $J = 7.2$  Hz, 3H);  $^{13}$ C-NMR (DMSO- $d_6$ , 150 MHz):  $\delta$  154.2, 149.8, 144.8, 137.7, 132.7, 130.1, 128.0, 127.1, 124.2, 37.4, 26.8, 21.1, 13.3.



**5-(2-ethoxyphenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one (4zh):** The product **4zh** was prepared by the General Procedure A using **1o** (36.8 mg, 0.2 mmol) and **2q** (36 mg, 0.24 mmol). The pure product was obtained by column chromatography on silica

gel using 20% acetone in hexanes as eluent. 40 mg (80%); white solid; The  $^1$ H NMR and  $^{13}$ C NMR spectra for this compound are consistent with previously reported literature data.<sup>21</sup>  $^1$ H-NMR ( $\text{CDCl}_3$ , 600 MHz):  $\delta$  11.11 (s, 1H), 8.44-8.46 (m, 1H), 7.45-7.42 (m, 1H), 7.12 (t,  $J = 8.4$  Hz, 1H), 7.02 (d,  $J = 8.4$  Hz, 1H), 4.25-4.28 (m, 5H), 2.92 (t,  $J = 7.8$  Hz, 2H), 1.83-1.89 (m, 2H), 1.59 (t,  $J = 7.2$  Hz, 3H), 1.02 (t,  $J = 7.2$  Hz, 3H);  $^{13}$ C-NMR ( $\text{CDCl}_3$ , 150 MHz):  $\delta$  156.6, 154.0, 148.5, 146.7, 138.8, 132.5, 131.2, 124.6, 121.9, 120.3, 113.0, 65.4, 38.3, 27.9, 22.5, 14.8, 14.2.





**2-(Quinolin-2-yl)quinazolin-4(3H)-one (6):** The product **6** was prepared by the General Procedure A (140 mol% of TFA, 120  $^{\circ}$ C, 24 h) using **1a** (27.2 mg, 0.2 mmol) and **2t** (36 mg, 0.24 mmol). The pure product was obtained by column chromatography on silica gel

using 20% ethyl acetate in hexanes as eluent. 34 mg (60 %); White solid; The  $^1$ H NMR and  $^{13}$ C NMR spectra for this




compound are consistent with previously reported literature data.<sup>22</sup> <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 600 MHz): δ 11.17 (s, 1H), 8.61 (d, *J* = 9.0 Hz, 1H), 8.36 (dd, *J* = 7.8, 1.2 Hz, 1H), 8.32 (d, *J* = 9.0 Hz, 1H), 8.12 (d, *J* = 9.0 Hz, 1H), 7.86 (t, *J* = 9.0 Hz, 2H), 7.80-7.76 (m, 2H), 7.60-7.62 (m, 1H), 7.53-7.51 (m, 1H); <sup>13</sup>C-NMR (CDCl<sub>3</sub>, 150 MHz): δ 161.6, 149.3, 149.1, 148.2, 146.9, 137.8, 134.7, 130.6, 129.8, 129.4, 128.4, 128.4, 127.9, 127.7, 126.9, 122.8, 118.6.

### Synthesis of Boucardatine in Scheme 5




**2-(1H-Indol-2-yl)quinazolin-4(3H)-one (5)** : The intermediate compound **8** was prepared by the General Procedure A (120 °C, 24 h) using **1a** (54 mg, 0.4 mmol) and **2s** (29 mg, 0.2 mmol). The residue was purified by column chromatography on silica gel (eluent: 20% ethyl acetate in hexanes) to give the desired products **5** (35 mg, 70% yield). Yellow solid; The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for this compound are consistent with previously reported literature data.<sup>23</sup> <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 600 MHz): δ 12.60 (s, 1H), 11.79 (s, 1H), 8.15 (d, *J* = 7.2 Hz, 1H), 7.85-7.83 (m, 1H), 7.72-7.74 (m, 1H), 7.66 (s, 1H), 7.63 (d, *J* = 8.4 Hz, 1H), 7.53-7.49 (m, 2H), 7.20-7.23 (m, 1H), 7.05 (t, *J* = 7.2 Hz, 1H); <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>, 150 MHz): δ 161.8, 148.7, 146.6, 137.7, 134.7, 130.0, 127.4, 126.9, 126.3, 126.1, 124.1, 121.5, 121.2, 120.0, 112.4, 105.0.




**Boucardatine (2-(4-Oxo-3,4-dihydroquinazolin-2-yl)-1H-indole-3-carbaldehyde)**: To a flask charged with a mixture of **5** (0.2 mmol, 52 mg) and FeCl<sub>3</sub>·6H<sub>2</sub>O (10 mol%) in DMF were added 37% HCHO solution in water (0.2 mmol, 16 μL) and 28-30% NH<sub>3</sub> solution in water (0.4 mmol, 27 μL). The reaction was stirred at 130 °C under air for 8 h. The reaction mixture was cooled down to ambient temperature and diluted with 5 mL of brine. The 0.5 mL of 0.5 M HCl was added to the mixture. The reaction mixture was further stirred for 30 min and extracted with ethyl acetate (10 mL x 5), washed with saturated

NaHCO<sub>3</sub> (10 mL x 2), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: 5% ethyl acetate in DCM) to give the desired product **Boucharlatine** in 65% yield (36 mg). The pure product was obtained by column chromatography on silica gel using 5% MeOH in DCM as eluent. 36 mg (65%); Yellow solid; The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for this compound are consistent with previously reported literature data.<sup>23</sup> <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 600 MHz): δ 13.60 (s, 1H), 13.10 (s, 1H), 10.46 (s, 1H), 8.25 (d, *J* = 8.4 Hz, 1H), 8.20 (d, *J* = 9.0 Hz, 1H), 7.92-7.89 (m, 1H), 7.84 (d, *J* = 8.4 Hz, 1H), 7.68 (d, *J* = 8.4 Hz, 1H), 7.58-7.60 (m, 1H), 7.39-7.41 (m, 1H), 7.32-7.34 (m, 1H); <sup>13</sup>C-NMR (DCMSO-d<sub>6</sub>, 150 MHz): δ 187.5, 161.2, 148.4, 145.3, 135.8, 135.7, 134.9, 127.6, 127.5, 127.4, 126.1, 125.4, 123.2, 121.8, 120.2, 115.1, 113.3.

### Synthesis of Sildenafil in Scheme 5




### 1) Synthesis of Benzyamine Derivative 2r



**Step 1:** To a flask charged with 3 mL of chlorosulfonic acid and 1 mL of Thionyl chloride was added 2-ethoxybenzamide (1.65 g, 10 mmol) at 0 °C under argon. The reaction mixture was stirred for 12 h below 20 °C. After reaction was complete by TLC, the reaction mixture was poured into chopped ice and the resulting product was extracted with dichloromethane (50 mL x 2), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The crude product was dissolved in 20 mL of dry dichloromethane and 1-methylpiperazine (2.44 mL, 20 mmol) was added to the mixture. The reaction was stirred for 30 min at 0 °C and then continued to stir at ambient temperature for 1 h. After the reaction was complete by TLC, 10 mL of water and 20 mL of saturated NH<sub>4</sub>Cl were added, respectively.

The reaction mixture was extracted with DCM, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated under reduced pressure. The desired product was purified by recrystallization in diethyl ether to give **2r-Benzamide** in 43% yield.




**2r-Benzamide (2-Ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)benzamide):** White solid, m.p.

199-200 °C; <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 600 MHz): δ 8.58 (d, *J* = 2.4 Hz, 1H), 7.82 (dd, *J* = 8.4, 2.4 Hz, 1H), 7.68 (s, 1H), 7.07 (d, *J* = 8.4 Hz, 1H), 6.25 (s, 1H), 4.26-4.29 (m, 2H), 2.92-3.16 (m, 4H), 2.38-2.54 (m, 4H), 2.25 (s, 3H), 1.54-1.56 (m, 3H); <sup>13</sup>C-NMR (CDCl<sub>3</sub>, 150 MHz): δ 165.3, 160.3,

133.0, 132.9, 128.1, 121.7, 112.7, 65.8, 54.1, 46.1, 45.8, 14.8; IR(neat): 3451, 3177, 2855, 2808, 1673, 1587, 1343, 1155 cm<sup>-1</sup>; HRMS (ESI): *m/z* calcd for C<sub>14</sub>H<sub>22</sub>N<sub>3</sub>O<sub>4</sub>S [M+H]<sup>+</sup> 328.1325 Found 328.1338.

**Step 2:** To a solution of **2r-Benzamide** (1.34 g, 4.1 mmol) in DCM (8mL) was added Et<sub>3</sub>N (2.28 mL, 16.4 mmol) at 0 °C under argon. After 5min, trifluoroacetic anhydride (1.27 mL, 9.0 mmol) was added dropwise. The reaction was stirred for 7 h at ambient temperature. The reaction mixture was diluted with DCM (15 mL) and saturated NaHCO<sub>3</sub> aqueous solution (5 mL) was added. After extracting with DCM, the combined organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The desired product was purified by column chromatography on silica gel (eluent: 5% MeOH in DCM) to provide **2r-Nitrile** in 90% yield.




**2r-Nitrile (2-Ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)benzonitrile):** Pale Yellow solid, m.p.

131-132 °C; <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 600 MHz): δ 7.90 (d, *J* = 2.4 Hz, 1H), 7.84 (dd, *J* = 9.0, 2.4 Hz, 1H), 7.05 (d, *J* = 9.0 Hz, 1H), 4.19-4.22 (m, 2H), 2.80-3.16 (m, 4H), 2.34-2.55 (m, 4H), 2.23 (s, 3H), 1.47-1.49 (m, 3H); <sup>13</sup>C-NMR (CDCl<sub>3</sub>, 150 MHz): δ 163.5, 134.0, 133.7, 127.8, 114.8, 112.4,

102.9, 65.8, 53.9, 46.0, 45.7, 14.3; IR(neat): 2991, 2804, 2228, 1590, 1490, 1334, 1133 cm<sup>-1</sup>; HRMS (ESI): *m/z* calcd for C<sub>14</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub>S [M+H]<sup>+</sup> 310.1219 Found 310.1230.

**Step 3:** **2r-Nitrile** (0.62 g, 2.0 mmol) was dissolved in the mixture of MeOH (10 mL) and conc. HCl (0.8 mL) and 10% Pd/C (120 mg) was added at ambient temperature under argon. The reaction atmosphere was then changed from argon to hydrogen and the solution was stirred for 48 h. After which, the reaction mixture was basified by adding the 1M NaOH solution (20 mL) and diluted with ethyl acetate (30 mL) and filtered through Celite. The filtrate was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: 3% NH<sub>4</sub>OH+15% CH<sub>3</sub>CN in DCM) to give the compound **2q** in 60% yield.



**(2-Ethoxy-4-((4-methylpiperazin-1-yl)sulfonyl)phenyl)methanamine (2r):** White solid, m.p.

179-180 °C; <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 600 MHz): δ 7.67 (d, *J* = 2.4 Hz, 1H), 7.59 (dd, *J* = 8.4, 2.4 Hz,


1H), 6.89 (d, *J* = 8.4 Hz, 1H), 4.09 (q, *J* = 7.2 Hz, 2H), 3.78 (s, 2H), 2.82-3.10 (m, 4H), 2.37-2.55

(m, 4H), 2.23 (s, 3H), 1.41 (t, *J* = 7.2 Hz, 3H); <sup>13</sup>C-NMR (CDCl<sub>3</sub>, 150 MHz): δ 160.5, 129.6, 129.0,

128.8, 126.4, 110.9, 64.2, 54.1, 47.9, 46.1, 45.8, 14.7; IR(neat): 3354, 2937, 2851, 2791, 1602, 1349, 1121 cm<sup>-1</sup>;

HRMS (ESI): *m/z* calcd for C<sub>14</sub>H<sub>24</sub>N<sub>3</sub>O<sub>3</sub>S [M+H]<sup>+</sup> 314.1532 Found 314.1540.

## 2) Synthesis and Characterization of Sildenafil



**Sildenafil (5-(2-ethoxy-4-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-1-methyl-3-**

**propyl-6,7a-dihydro-1H-pyrazolo[4,3-*d*]pyrimidin-7(3aH)-one):** Sildenafil was prepared

by the General Procedure A (150 °C, 24 h) using **1o** (0.2 mmol, 36.4 mg) and **2r** (0.24 mmol,

75 mg). The residue was purified by column chromatography on silica gel (eluent: 1% MeOH

in dichloromethane). 47 mg (50%); white solid; The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for this

compound are consistent with previously reported literature data.<sup>21</sup> <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 600 MHz): δ 10.82 (s, 1H), 8.81

(d, *J* = 2.4 Hz, 1H), 7.82 (dd, *J* = 8.4, 2.4 Hz, 1H), 7.14 (d, *J* = 8.4 Hz, 1H), 4.34-4.38 (m, 2H), 4.27 (s, 3H), 3.10 (m,

4H), 2.90-2.93 (m, 2H), 2.50 (m, 4H), 2.27 (s, 3H), 1.83-1.86 (m, 2H), 1.62-1.64 (m, 3H), 1.01 (t, *J* = 7.8 Hz, 3H);

<sup>13</sup>C-NMR (CDCl<sub>3</sub>, 150 MHz): δ 159.4, 153.8, 147.1, 146.5, 138.5, 131.8, 131.3, 129.0, 124.6, 121.2, 113.2, 66.2, 54.2,

46.1, 45.8, 38.4, 27.9, 22.4, 14.7, 14.2.



## References

1. Parua, S. P.; Das, S.; Sikari, R.; Sinha, S.; Paul, N. D. One-Pot Cascade Synthesis of Quinazolin-4(3H)-ones via Nickel-Catalyzed Dehydrogenative Coupling of *o*-Aminobenzamides with Alcohols. *J. Org. Chem.* **2017**, *82*, 7165-7175.
2. Dhiman, S.; Saini, H. K.; Nandwana, N. K.; Kumar, D. Copper-Catalyzed Synthesis of Quinoline Derivatives via Tandem Knoevenagel Condensation, Amination and Cyclization. *RSC Adv.* **2016**, *6*, 23987-23994.
3. Tu, T.; Wang, Z.; Liu, Z.; Feng, X.; Wang, Q. Efficient and Practical Transition Metal-Free Catalytic


- Hydration of Organonitriles to amides. *Green Chem.* **2012**, *14*, 921-924.
- Mizutani, T.; Nagase, T.; Ito, S.; Miyamoto, Y.; Tanaka, T.; Takenaga, N.; Tokita, S.; Sato, N. Development of Novel 2-[4-(Aminoalkoxy)phenyl]-4(3*H*)-Quinazolinone Derivatives as Potent and Selective Histamine H<sub>3</sub> Receptor Inverse Agonists. *Bioorg. Med. Chem.* **2008**, *18*, 6041-6045.
  - Sutherland, C.; Ley, S. V. On the Synthesis and Reactivity of 2,3-Dihydropyrrolo[1,2-*a*]quinazolin-5(1*H*)-ones. *Synthesis* **2017**, *49*, 135-144.
  - Long, L.; Wang, Y. H.; Zhuo, J. X.; Tu, Z. C.; Wu, R.; Yan, M.; Liu, Q.; Lu, G. Structure-Based Drug Design: Synthesis and Biological Evaluation of Quinazolin-4-amine Derivatives as Selective Aurora A kinase inhibitors. *Eur. J. Med. Chem.* **2018**, *157*, 1361-1375.
  - Nathubhai, A.; Haikarainen, T.; Hayward, P. C.; Muñoz-Descalzo, S.; Thompson, A. S.; Lloyd, M. D.; Lehtiö, L.; Threadgill, M. D. Structure-Activity Relationships of 2-Arylquinazolin-4-ones as Highly Selective and Potent Inhibitors of the Tankyrases. *Eur. J. Med. Chem.* **2016**, *118*, 316-327.
  - Wang, Z.; Tang, Y. Mechanistic Insights into a Catalyst-Free Method to Construct Quinazolinones through Multiple Oxidative Cyclization. *Tetrahedron* **2016**, *72*, 1330-1336.
  - (a) Kim, H. Y.; Oh, K. A Facile Access to 4-Substituted-2-naphthols *via* a Tandem Friedel-Crafts Reaction: A  $\beta$ -Chlorovinyl Ketone Pathway. *Org. Lett.* **2014**, *16*, 5934-5936; (b) Kim, H. Y.; Takizawa, S.; Oh, K. Copper-catalyzed Divergent Oxidative Pathways of 2-Naphthol Derivatives: *ortho*-Naphthoquinones *versus* 2-BINOLs. *Org. Biomol. Chem.* **2016**, *14*, 7191-7196; (c) Goriya, Y.; Kim, H. Y.; Oh, K. *o*-Naphthoquinone-catalyzed Aerobic Oxidation of Amines to (Ket)imines: A Modular Catalyst Approach. *Org. Lett.* **2016**, *18*, 5174-5177.
  - Hikawa, H.; Ino, Y.; Suzuki, H.; Yokoyama, Y. Pd-Catalyzed Benzylic C-H Amidation with Benzyl Alcohols in Water: A Strategy to Construct Quinazolinones. *J. Org. Chem.* **2012**, *77*, 7046-7051.
  - Zhou, J.; Fang, J. One-pot Synthesis of Quinazolinones via Iridium-Catalyzed Hydrogen Transfers. *J. Org. Chem.* **2011**, *76*, 7730-7736.
  - Tian, X.; Song, L.; Li, E.; Wang, Q.; Yu, W.; Chang, J. Metal-free One-pot Synthesis of 1,3-Diazaheterocyclic Compounds via I<sub>2</sub>-Mediated Oxidative C-N Bond Formation. *RSC Adv.* **2015**, *5*, 62194-62201.
  - Hu, Y.; Chen, L.; Li, B. Iron Nitrate/TEMPO-catalyzed Aerobic Oxidative Synthesis of Quinazolinones




- from Alcohols and 2-Aminobenzamides with Air as the Oxidant. *RSC. Adv.* **2016**, *6*, 65196-65204.
14. Liu, W.; Gao, W.; Ding, J.; Huang, X.; Liu, M.; Wu, H. Palladium-catalyzed Oxidative C=C Bond Cleavage with Molecular Oxygen: One-pot Synthesis of Quinazolinones from 2-Amino Benzamides and Alkenes. *Org. Chem. Front.* **2018**, *5*, 2734-2738.
  15. Iqbal, M. A.; Lu, L.; Mehmood, H.; Khan, D. M.; Hua, R. Quinazolinone Synthesis through Base-Promoted  $S_NAr$  Reaction of *ortho*-Fluorobenzamides with Amides Followed by Cyclization. *ACS Omega*, **2019**, *4*, 8207-8213.
  16. Wang, Q.; Lv, M.; Liu, J.; Li, Y.; Xu, Q.; Zhang, X.; Cao, H. Efficient Synthesis of Quinazolinones by Transition-Metal-Free Direct Aerobic Oxidative Cascade Annulation of Alcohols with *o*-Aminoarylnitriles. *ChemSusChem*, **2019**, *12*, 3043-3048.
  17. Xu, W.; Jin, Y.; Liu, H.; Jiang, Y.; Fu, H. Copper-Catalyzed Domino Synthesis of Quinazolinones via Ullmann-Type Coupling and Aerobic Oxidative C-H Amidation. *Org. Lett.* **2011**, *13*, 1274-1277.
  18. Yang, X.; Cheng, G.; Shen, J.; Kuai, C.; Cui, X. Cleavage of the C-C Triple Bond of Ketoalkynes: Synthesis of 4(3*H*)-Quinazolinones. *Org. Chem. Front.* **2015**, *2*, 366-368.
  19. Chen, K.; Gao, B.; Shang, Y.; Du, J.; Gu, Q.; Wang, J.  $I_2$ -Catalyzed Cross Dehydrogenative Coupling: Rapid Access to Benzoxazinones and Quinazolinones. *Org. Biomol. Chem.* **2017**, *15*, 8770-8779.
  20. Krapf, M. K.; Gallus, J.; Vahdati, S.; Wisnes, M. New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold. *J. Med. Chem.* **2018**, *61*, 3389-3408.
  21. Laha, J. K.; Patel, K. V.; Tummalapalli, S.; Dayal, N. Formation of Amides, their Intramolecular Reactions for the Synthesis of *N*-Heterocycles, and Preparation of a Marketed Drug, Sildenafil: A Comprehensive Coverage. *Chem. Commun.* **2016**, *52*, 10245-10248.
  22. Liu, H.; Zhai, T.; Ding, S.; Hou, Y.; Zhang, X.; Feng, L.; Ma, C. Direct and Metal-Free Oxidative Amination of  $sp^3$  C-H bonds for the Construction of 2-hetarylquinazolin-4(3*H*)-ones. *Org. Chem. Front.* **2016**, *3*, 1096-1099.
  23. Viji, M.; Nagarajan, R. Copper-Catalysed Synthesis of Indolylquinazolinone Alkaloid Bouchardatine. *J. Chem. Sci.* **2014**, *126*, 1075-1080.

Spectra:





**1d**















**1f**








**1g**








**1h**








**1i**








11









**2r-Benzamide**







**2r-Nitrile**















**3a**









**4a**








**4b**












**4d**









4e







4f















4h








4i








4j








4k








41








**4m**






**4n**








**40**












4p








4q








**4r**








4s








4t








4u






4v








**4w**












4x








4y








4z








**4za**








**4zb**








4zc






**4zd**








4ze













**4zf**












**4zh**








5








**Bouchardatine**





**Sildenafil**





6

